Epitomee Medical

Company Overview

Snapshot

Founded in August 2005 by Dr. Shimon Eckhouse, Epitomee Medical operates with 11–50 employees. The company has raised $77 million across 4 funding rounds from 6 investors. Epitomee Medical went public on the TASE in December 2021, achieving a valuation of $203 million.

Business overview

Epitomee Medical is a public company focused on developing and commercializing ingestible therapeutic devices to address prevalent chronic diseases. Its core technology utilizes self-expanding hydro-gel scaffolds, folded into standard pharmaceutical capsules, made from biocompatible excipients and food additives. These hydro-gel scaffolds can be engineered to activate at specific pH levels, enabling targeted delivery for optimal therapeutic effects. The company operates within the Health Tech & Life Sciences sector, specifically in Medical Devices and Medical Treatment & Therapeutics, serving both healthcare industries and consumers globally.

Strategic signal

In September 2024, Epitomee Medical announced FDA clearance for its capsule weight management device. This regulatory approval is a significant validation of the company's technology and opens a critical market pathway in the United States, signaling strong commercial potential and de-risking for investors in the competitive weight management and medical device sectors.

Company Intelligence Q&A

What was a significant recent regulatory milestone for Epitomee Medical?

In September 2024, Epitomee Medical announced that the United States Food and Drug Administration (FDA) officially cleared its Epitomee® capsule weight management device.

When did Epitomee Medical complete patient enrollment for its weight loss capsule pivotal study in the United States?

In March 2023, Epitomee and Nestlé Health Science announced the completion of patient enrollment in Epitomee's weight loss capsule pivotal study in the United States.

What was the outcome of the RESET Study for Epitomee's drug-free capsule?

In November 2024, results from the RESET Study, demonstrating Epitomee's drug-free capsule helps patients shed pounds, were presented at ObesityWeek® 2024.

What was a key strategic partnership announced by Epitomee Medical?

In August 2020, Epitomee Medical Ltd. and Nestlé Health Science announced a partnership for the development and commercialization of the Epitomee weight loss capsule.

When did Epitomee Medical go public?

Epitomee Medical went public on the TASE in December 2021, achieving a valuation of $203 million.